Sodium glucose co-transporter (SGLT)2 inhibitors are a relatively new class of oral glucose lowering agents originally developed for the treatment of type 2 diabetes. SGLT2 inhibitors do not only improve glycemic control. Large clinical trials in patients with cardiovascular and chronic kidney disease have demonstrated that these drugs reduce the relative risk of heart failure and end-stage kidney disease by 30 to 40%. Interestingly, the most recent clinical trials demonstrated that the benefits of SGLT2 inhibitors on clinical endpoints were present regardless of diabetes status. These data indicate that the indication for SGLT2 inhibitors extend beyond type 2 diabetes and that these drugs have important clinical consequences for many patients with heart failure and CKD. While the clinical benefits and safety profile have been well established in the past 5 years several outstanding questions remain.
Regarding the mechanism of kidney and heart failure protection of SGLT2 inhibitors and strategies for how to best implement these new agents in the clinical management of patients with CKD. The key topics we propose to address in this issue are: 1) How do SGLT2 inhibitors precisely protect heart and kidney function? 2) How do we best implement the findings from clinical trials in clinical practice? 3) What is the optimal position of SGLT2 inhibitors next to many other drugs used in patients with heart failure and chronic kidney disease? 4) What is the role for combination therapies?
In this special issue of Frontiers we solicit original research articles, commentaries, opinions and reviews about SGLT2 inhibitors in patients with CKD. The articles should deal with any of the following topics including but not limited to the below:
• Mechanism of action of SGLT2 inhibitors with respect to heart and kidney protection. Pre-clinical and clinical studies can be submitted.
• Opinions and perspectives how SGLT2 inhibitors modify the cardio-renal axis.
• Interaction of SGLT2 inhibitors with other cardiorenal protective agents as well as gaps in trials looking into combination therapies trials with SGLT2 (ie GLP-1 RA, finerenone)
• Integrated discussion with respect to the different guidelines across the medical specialties
Sodium glucose co-transporter (SGLT)2 inhibitors are a relatively new class of oral glucose lowering agents originally developed for the treatment of type 2 diabetes. SGLT2 inhibitors do not only improve glycemic control. Large clinical trials in patients with cardiovascular and chronic kidney disease have demonstrated that these drugs reduce the relative risk of heart failure and end-stage kidney disease by 30 to 40%. Interestingly, the most recent clinical trials demonstrated that the benefits of SGLT2 inhibitors on clinical endpoints were present regardless of diabetes status. These data indicate that the indication for SGLT2 inhibitors extend beyond type 2 diabetes and that these drugs have important clinical consequences for many patients with heart failure and CKD. While the clinical benefits and safety profile have been well established in the past 5 years several outstanding questions remain.
Regarding the mechanism of kidney and heart failure protection of SGLT2 inhibitors and strategies for how to best implement these new agents in the clinical management of patients with CKD. The key topics we propose to address in this issue are: 1) How do SGLT2 inhibitors precisely protect heart and kidney function? 2) How do we best implement the findings from clinical trials in clinical practice? 3) What is the optimal position of SGLT2 inhibitors next to many other drugs used in patients with heart failure and chronic kidney disease? 4) What is the role for combination therapies?
In this special issue of Frontiers we solicit original research articles, commentaries, opinions and reviews about SGLT2 inhibitors in patients with CKD. The articles should deal with any of the following topics including but not limited to the below:
• Mechanism of action of SGLT2 inhibitors with respect to heart and kidney protection. Pre-clinical and clinical studies can be submitted.
• Opinions and perspectives how SGLT2 inhibitors modify the cardio-renal axis.
• Interaction of SGLT2 inhibitors with other cardiorenal protective agents as well as gaps in trials looking into combination therapies trials with SGLT2 (ie GLP-1 RA, finerenone)
• Integrated discussion with respect to the different guidelines across the medical specialties